The study showed that tirzepatide could significantly lower the risk of developing diabetes in people with prediabetes, demonstrating a potential treatment pathway for at-risk patients.
Tirzepatide’s action on GLP-1 and GIP hormones provides dual benefits for those with prediabetes, aiding not only in weight loss but also in glycemic control.
Dr. Michael Weintraub emphasizes the importance of a medication for prediabetes, indicating that early intervention could substantially impact public health outcomes.
With a 94% reduction in diabetes progression risk among participants, the study advocates for the drug's potential use as a preventative treatment for at-risk individuals.
Collection
[
|
...
]